Sudoterb, also known as LL3858, is an anti-tubercular drug candidate. It exhibits potent activity against Mycobacterium tuberculosis, including multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains. Its mechanism of action is believed to involve inhibition of bacterial ATP synthase, similar to bedaquiline, leading to energy depletion in M. tuberculosis. In vitro, LL3858 has demonstrated a minimum inhibitory concentration (MIC) in the low micromolar to submicromolar range, with reported MIC₉₀ values around 0.06–0.5 µg/mL. Preclinical efficacy studies in murine TB models showed significant reduction in bacterial load in both lung and spleen tissues when administered orally. LL3858 advanced to Phase I clinical trials in India, where it was found to be generally well tolerated, although its development was reportedly paused due to strategic shifts. Nonetheless, it remains a notable candidate from the Indian TB drug discovery pipeline, offering a promising alternative to current anti-TB therapies.
MedKoo Cat#: 206788
Name: Sudoterb free base
CAS#: 676266-31-2 (free base)
Chemical Formula: C29H28F3N5O
Exact Mass: 519.2246
Molecular Weight: 519.57
Elemental Analysis: C, 67.04; H, 5.43; F, 10.97; N, 13.48; O, 3.08
The following data is based on the product molecular weight 519.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
